Genetic determinants of response to patritumab deruxtecan (HER3-DXd) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer: a correlative analysis from SOLTI TOT-HER3 trial
Brasó-Maristany, F; Falato, C; Martínez-Sáez, O; Cejalvo, JM; Margelí, M; Tolosa, P; Bofill, FJS; Cruz, J; González-Farré, B; Sanfeliu, E; Arumi, M; Villacampa, G; Ciruelos, E; Espinosa-Bravo, M; Izarzuzaga, Y; Galván, P; Matito, J; Pernas, S; Santhanagopal, A; Esker, S; Patel, P; Fan, PD; Ferrero-Cafiero, JM; Vivancos, A; Pascual, T; Prat, A; Oliveira, M; Ferrero-Cafiero, JM; Vivancos, A; Pascual, T; Prat, A; Oliveira, M
CANCER RESEARCH, 2023; 83 (5):
